Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

This study is comparing two treatment approaches for people with rheumatoid arthritis (a condition where the immune system attacks the joints) who have not improved enough on their current medication — one approach adds a targeted biologic drug, while the other combines three existing medications. **You may be eligible if...** - You have been diagnosed with rheumatoid arthritis - Your disease is still moderately to severely active despite treatment - You have been taking methotrexate or leflunomide for at least 3 months at the recommended dose without enough improvement - You have signs of joint damage on X-rays or specific antibodies in your blood (rheumatoid factor or anti-CCP) - You are 18 years or older - Women of childbearing age must have a negative pregnancy test and use effective contraception **You may NOT be eligible if...** - You are pregnant or not using reliable birth control - You have had a serious reaction to the study medications before - You have other significant health conditions that would interfere with the study Talk to your doctor to see if this trial is right for you.